ArticleTranslational cancer research2026
Identification of necrosis-related signature for predicting prognosis and immunotherapy response in gastric cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is an important malignancy of the digestive system with a high lethal rate. Emerging evidence implicates necrosis-related genes (NRGs) as key regulators of GC progression; however, their specific mechanisms of action within the tumor microenvironment (TME), particularly regarding immune and stromal cell interactions, require further characterization. This study investigates the functional roles and clinical relevance of NRGs in shaping the GC TME. Methods: Utilizing clinical and transcriptomic profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, we systematically evaluated 159 necrosis-associated genes in GC. Through differential expression analysis and functional validation, 24 genes demonstrating significant necrosis-related dysregulation were identified. Applying consensus clustering to transcriptomic profiles, we delineated three molecularly distinct necrosis subtypes in GC. These subtypes dynamically regulate distinct pathobiological cascades, functionally link to disease aggressiveness metrics, sculpt tumor immune ecosystems, and stratify patients into differential survival probability groups. Subsequently, we formulated a scoring system termed necrosis score, which was calculated to quantify the different NRG clusters of the individual GC. Results: Integrative analysis revealed a significant negative correlation between necrosis scores and immunogenic biomarkers [programmed death-ligand 1 (PD-L1) expression, tumor mutational burden (TMB), microsatellite instability-high (MSI-H) status], identifying a patient subset with enhanced immunotherapy response rates and superior survival outcomes. The opposite was observed in the high-necrosis score group. Conclusions: Collectively, necrosis subtypes are involved in TME, clinicopathological characteristics, and prognosis. Necrosis score could serve as a potential biomarker for GC and provide a new perspective on developing personalized immune therapeutic strategies for GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.